In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Radioligands Advance Radiotherapy Premise With Greater Precision

Executive Summary

With the successful launch of Novartis’ Pluvicto and Lutathera, more firms are developing radioligands in the hopes of mitigating side effects and addressing unmet needs in cancer. 

You may also be interested in...



Abdera Comes Out Of Stealth With Radiopharmaceutical-Specialized Antibody Approach

The company has sought to develop antibodies purpose-built for delivering radiotherapy rather than repurposing existing antibodies for that purpose, as some other players have done.

New Data Bolster Prospects For Actinium's Radioligand

The US firm has announced positive survival data from a Phase III trial of it radioligand therapy, Iomab-B, in acute myeloid leukemia patients prior to bone transplant, improving its cost-effectiveness case and commercial strategy.

Finance Watch: Third Harmonic Launches The Largest IPO In Months

Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV146667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel